Particles in Biopharmaceutical Formulations, Part 2: An Update on Analytical Techniques and Applications for Therapeutic Proteins, Viruses, Vaccines and Cells
Roesch A, et al. J Pharm Sci. 2021 Dec, S0022-3549(21)00689-4
Miniaturized Forced Degradation of Therapeutic Proteins and ADCs by Agitation-Induced Aggregation using Orbital Shaking of Microplates
Johann F, et al. J Pharm Sci. 2021 Sept, S0022-3549(21)00497-4
Analysis of Aggregates and Particles
Cheng Y, Saggu M, and Thomas JC, Protein Instability at Interfaces During Drug Product Development, 2021 Feb, pp 199-266
Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension To Predict Surfactant Requirements for Biological Formulations
Vargo KB, Wu Z, and Gupta S. Mol Pharm. 2021 Jan, 18(1):148-157
Developability Assessment for Monoclonal Antibody Drug Candidates: A Case Study
Garripelli VK, et al., Pharm Dev Technol, 2021 Jan, 26(1):11-20
A Rapid, Small-Volume Approach To Evaluate Protein Aggregation at Air-Water Interfaces
Wood CV, et al., J Pharm Sci, 2020 Nov, doi: 10.1016/j.xphs.2020.11.024
A Comparison of Background Membrane Imaging Versus Flow Technologies for Subvisible Particle Analysis of Biologics
Vargas SK, et al, Int J Pharm, 2020 Mar, 578:119072
Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development
Helbig C, et al., J Pharm Sci, 2020 Jan, 109(1):264-276
What Makes Polysorbate Functional? Impact of Polysorbate 80 Grade and Quality on IgG Stability During Mechanical Stress
Grabarek AD, et al., J Pharm Sci, 2020 Jan, 109(1):871-880
